Search - tctmd.com

Displaying 101 - 120 of 697

Sort: Relevancy | Date

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

News Conference News LINC 2020

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

L.A. McKeown

February 06, 2020

News Conference News LINC 2020

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

L.A. McKeown

January 31, 2020

News Conference News LINC 2020

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

L.A. McKeown

January 30, 2020

News Conference News LINC 2020

Lutonix BTK Studies: Below-the-Knee Challenges Linger

L.A. McKeown

January 29, 2020

News Conference News LINC 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

L.A. McKeown

January 28, 2020

News Conference News ISET 2020

Venous Stents: Long-term Follow-up Plus a New Contender

Caitlin E. Cox

January 24, 2020

News Daily News

Paclitaxel DCBs Now Implicated in Death, Amputation in Below-the-Knee CLI

L.A. McKeown

January 15, 2020

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

News Conference News VIVA 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

L.A. McKeown

November 05, 2019

News Industry News

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

October 09, 2019

News Conference News TCT 2019

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

Caitlin E. Cox

October 08, 2019

News Conference News TCT 2019

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

L.A. McKeown

October 04, 2019

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

L.A. McKeown

September 28, 2019

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Caitlin E. Cox

September 10, 2019

News Industry News

2nd ‘Breakthrough Device Designation’ granted to Concept Medical Inc. by FDA for MagicTouch PTA Sirolimus Coated Balloon

August 13, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

L.A. McKeown

June 20, 2019

News Conference News EuroPCR 2019

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Michael O'Riordan

May 27, 2019

News Industry News

EFFPAC RCT 24-month has revealed in EuroPCR 2019 that Luminor DCB demonstrate a non-increase of risk of death at 24-month follow-up

May 23, 2019

Advertisement

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

Lutonix BTK Studies: Below-the-Knee Challenges Linger

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

Venous Stents: Long-term Follow-up Plus a New Contender

Paclitaxel DCBs Now Implicated in Death, Amputation in Below-the-Knee CLI

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

2nd ‘Breakthrough Device Designation’ granted to Concept Medical Inc. by FDA for MagicTouch PTA Sirolimus Coated Balloon

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

EFFPAC RCT 24-month has revealed in EuroPCR 2019 that Luminor DCB demonstrate a non-increase of risk of death at 24-month follow-up

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content